NCT06777420 Question Prompt List in Breast Cancer Patients Planned for Neoadjuvant Chemotherapy
| NCT ID | NCT06777420 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Region Örebro County |
| Condition | Breast Cancer Early Stage Breast Cancer (Stage 1-3) |
| Study Type | INTERVENTIONAL |
| Enrollment | 218 participants |
| Start Date | 2025-03-01 |
| Primary Completion | 2027-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 218 participants in total. It began in 2025-03-01 with a primary completion date of 2027-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Preoperative chemotherapy has been shown to be at least as effective as postoperative chemotherapy in breast cancer patients and has seen increased use over time. The decision regarding neoadjuvant treatment is complex, as various aspects need to be considered, and the patient's role in the decision-making process is central. The information provided by doctors to patients about preoperative treatment can be complicated, including details about treatment options, treatment plans, and side effects. If this information is not conveyed adequately, there is a risk of misunderstandings, which can lead to increased anxiety and stress for patients regarding their decisions. In oncology, question prompt lists (QPL) have been used as a tool to support patients by improving the information conveyed by doctors in various contexts where complex decisions need to be made. Studies have shown that QPL can facilitate better information exchange. However, their use in discussions about preoperative treatment for breast cancer patients has not been studied. Furthermore, evidence from randomized studies on the use of QPL in clinical practice is very limited. The aim of this study is to investigate whether the use of QPL during patient consultations involving discussions about neoadjuvant chemotherapy can improve information exchange in various aspects: understanding of the treatment; anxiety about the decision; participation in the decision-making process; patient-doctor communication; and decision-related conflict.
Eligibility Criteria
Inclusion Criteria: * Patients with operable breast cancer eligible for systemic neoadjuvant therapy, according to current treatment guidelines. Exclusion Criteria: * Patients with locally advanced breast cancer where neoadjuvant therapy is mandatory rather than a treatment option. * Patients with cognitive impairment that are assessed from treating physician as unable to participate. * Patients who cannot speak/read neither Swedish nor English.
Contact & Investigator
Antonis Valachis, MD, PhD
PRINCIPAL INVESTIGATOR
Department of Oncology, Örebro University Hospital, Sweden
Frequently Asked Questions
Who can join the NCT06777420 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer Early Stage Breast Cancer (Stage 1-3). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06777420 currently recruiting?
Yes, NCT06777420 is actively recruiting participants. Contact the research team at antonios.valachis@regionorebrolan.se for enrollment information.
Where is the NCT06777420 trial being conducted?
This trial is being conducted at Uppsala, Sweden, Västerås, Sweden, Örebro, Sweden.
Who is sponsoring the NCT06777420 clinical trial?
NCT06777420 is sponsored by Region Örebro County. The principal investigator is Antonis Valachis, MD, PhD at Department of Oncology, Örebro University Hospital, Sweden. The trial plans to enroll 218 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.